Axsome Malta Ltd v. Aurobindo Pharma USA Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Axsome Malta Ltd. (Malta) and Axsome Therapeutics, Inc. (Delaware)
  • Defendant: Aurobindo Pharma USA, Inc. (Delaware) and Aurobindo Pharma Limited (India)
  • Plaintiff's Counsel: Saul Ewing LLP
• Case Identification: Axsome Malta Ltd. v. Aurobindo Pharma USA, Inc., 2:26-cv-01580, D.N.J., 02/18/2026
• Venue Allegations: Venue in the District of New Jersey is asserted based on Defendant Aurobindo Pharma USA, Inc.'s established physical place of business in the state, its registration to conduct business there, and its purposeful availment of the district. For Aurobindo Pharma Limited, a foreign corporation, venue is alleged to be proper as it is not subject to general jurisdiction in any state and has sufficient contacts with the United States as a whole.
• Core Dispute: Plaintiff alleges that Defendant's filing of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiff's Sunosi® (solriamfetol) oral tablets constitutes an act of infringement of a patent covering crystalline forms of the drug.
• Technical Context: The dispute is in the field of pharmaceutical chemistry, focusing on the specific crystalline solid-state form (polymorph) of an active pharmaceutical ingredient used in a drug for treating excessive daytime sleepiness.
• Key Procedural History: This is a Hatch-Waxman action triggered by Defendant Aurobindo's submission of a Paragraph IV certification to the FDA, alleging that U.S. Patent No. 12,384,743 is invalid and/or will not be infringed by its proposed generic product. The complaint notes that other patents in the same family are the subject of separate, currently pending litigation between Axsome and Aurobindo, as well as other generic manufacturers.

Case Timeline

Date	Event
2016-09-06	'743 Patent Priority Date
2025-08-12	'743 Patent Issue Date
2026-02-18	Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,384,743 - Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof

• Patent Identification: U.S. Patent No. 12,384,743, "Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof," issued August 12, 2025.

The Invention Explained

• Problem Addressed: The patent describes issues that can arise during the manufacturing of the active pharmaceutical ingredient (API) (R)-2-amino-3-phenylpropyl carbamate (APC), the active ingredient in Sunosi®. Specifically, the background notes the desirability of providing a new form of the drug and a method for preparing it with "minimal contaminants" '743 Patent, col. 1:44-47 A significant manufacturing challenge identified is the formation of "unacceptable levels of the impurity 2-chloropropane," which is described as a "potential genotoxic impurity" that can appear during the crystallization of APC hydrochloride '743 Patent, col. 6:40-44
• The Patented Solution: The patent discloses newly identified crystalline forms of APC hydrochloride, including a hemihydrate "Form B," and an anhydrous "Form A" '743 Patent, col. 4:36-44 The claims are directed to the specific crystalline Form A '743 Patent, claim 1 The specification also describes an improved crystallization process using aqueous HCl, which minimizes the formation of the genotoxic 2-chloropropane impurity ('743 Patent, col. 6:47-54).
• Technical Importance: Controlling the specific crystalline form (polymorphism) and purity of an API is critical in pharmaceutical development for ensuring consistent safety, stability, bioavailability, and manufacturability, as well as for meeting stringent regulatory standards.

Key Claims at a Glance

• The complaint asserts infringement of at least independent claim 1 '743 Patent, claim 1 Compl. ¶30
• The essential element of independent claim 1 is:
  • Crystalline (R)-2-amino-3-phenylpropyl carbamate hydrochloride having an X-ray powder diffraction pattern as shown in FIG. 1 Form A.
• The complaint alleges infringement of "one or more of the claims" of the patent '743 Patent, claim 1 Compl. ¶30

III. The Accused Instrumentality

Product Identification

• The accused instrumentality is Defendant Aurobindo's proposed generic solriamfetol oral tablets, for which it seeks FDA approval via Abbreviated New Drug Application (ANDA) No. 218725 '743 Patent, claim 1 Compl. ¶1 Compl. ¶15

Functionality and Market Context

• The proposed product is a generic version of Axsome's branded drug, Sunosi®, which is a dopamine and norepinephrine reuptake inhibitor (DNRI) '743 Patent, claim 1 Compl. ¶2 Compl. ¶9 It is intended to be a therapeutically equivalent and lower-cost alternative for improving wakefulness in patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea '743 Patent, claim 1 Compl. ¶2 Compl. ¶9 The filing of the ANDA itself represents a significant commercial step towards market entry prior to the patent's expiration '743 Patent, claim 1 Compl. ¶1

IV. Analysis of Infringement Allegations

The complaint does not provide a detailed claim chart. The infringement theory is based on the statutory act of infringement under the Hatch-Waxman Act, where filing an ANDA for a drug claimed in a patent is a technical act of infringement to create federal court jurisdiction.

'743 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
Crystalline (R)-2-amino-3-phenylpropyl carbamate hydrochloride having an X-ray powder diffraction pattern as shown in FIG. 1 Form A.	The complaint alleges that Aurobindo's submission of its ANDA for a generic version of solriamfetol oral tablets, prior to the expiration of the '743 patent, constitutes infringement of one or more claims of the patent, including at least claim 1. This implies the proposed generic product contains the claimed crystalline form.	¶30; ¶32	col. 12:32-35

No probative visual evidence provided in complaint.

• Identified Points of Contention:
  • Scope Questions: The case will likely hinge on the comparison between the crystalline form of the API in Aurobindo's ANDA product and the specific "Form A" defined in claim 1. A central question is whether the claim language "having an X-ray powder diffraction pattern as shown in FIG. 1 Form A" requires an exact match to the figure or allows for some degree of variation common in such measurements.
  • Technical Questions: A key evidentiary question is what the actual crystal structure of the solriamfetol hydrochloride in Aurobindo's proposed product is. Aurobindo's Paragraph IV certification of non-infringement suggests it will argue that its API is a different polymorph or is otherwise outside the scope of claim 1 '743 Patent, claim 1 Compl. ¶26 Compl. ¶28 The outcome will depend on detailed scientific characterization (e.g., XRPD, DSC) of both the patented and accused materials.

V. Key Claim Terms for Construction

• The Term: "having an X-ray powder diffraction pattern as shown in FIG. 1 Form A"
• Context and Importance: This phrase is not just a term but the defining limitation of the claim, establishing its scope through a reference to a specific property depicted in a figure. Practitioners may focus on this phrase because the entire infringement analysis for this product-by-property claim rests on comparing the accused product's physical properties to this benchmark. The degree of identity required by "as shown" will be a critical issue.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: A party could argue that in the context of XRPD analysis, "as shown" should be understood by a person of ordinary skill in the art to encompass minor, non-material variations in peak position and intensity that can result from differences in sample preparation or instrumentation, as long as the overall pattern is recognizably that of Form A. The patent's summary describes another form (Form B) as having a pattern "substantially the same as that shown in FIG. 1," which might suggest the inventors knew how to use qualifying language and its absence in claim 1 was not intended to impose an extreme standard of identity '743 Patent, col. 1:60-61
  • Evidence for a Narrower Interpretation: A party could argue that the plain language "as shown," without a modifier like "substantially," requires a very close or identical match to the pattern depicted in FIG. 1. The patent clearly distinguishes between Form A, Form B, and other materials in FIG. 1, suggesting that the patterns are meant to be precise identifiers for distinct crystalline forms '743 Patent, FIG. 1 The choice to claim "Form A" specifically by reference to its figure, rather than by a set of characteristic peak locations, could be argued to impart a narrow scope tied directly to that graphical representation '743 Patent, claim 1

VI. Other Allegations

• Indirect Infringement: The complaint alleges that upon approval, Aurobindo will induce infringement by making, using, and selling its product in the United States with knowledge of the patent and with the intent to encourage infringement '743 Patent, claim 1 Compl. ¶33 It also alleges contributory infringement, stating that Aurobindo's product is designed for an infringing use and lacks a substantial non-infringing use '743 Patent, claim 1 Compl. ¶34
• Willful Infringement: The complaint does not use the word "willful," but it does allege that Aurobindo had knowledge of the '743 patent, as evidenced by its Paragraph IV certification '743 Patent, claim 1 Compl. ¶28 It further requests a judgment that the case is "exceptional" pursuant to 35 U.S.C. § 285, which allows for an award of attorneys' fees and is often associated with findings of inequitable conduct or litigation misconduct, but can also be supported by findings of willful infringement '743 Patent, claim 1 Compl. ¶37 Compl., prayer J

VII. Analyst's Conclusion: Key Questions for the Case

This case appears to be a classic pharmaceutical dispute centered on polymorphism. The primary questions for the court will likely be:

• A central question will be one of polymorphic identity: does the active pharmaceutical ingredient in Aurobindo's proposed generic product consist of the specific "Form A" crystal structure as defined by claim 1 of the '743 patent, or has Aurobindo developed a different, non-infringing form? This is a factual determination that will be resolved through competing scientific evidence.
• A related legal question will be one of claim scope: how should the court interpret the phrase "as shown in FIG. 1 Form A"? The strictness of this comparison-whether it requires near-perfect identity or allows for typical analytical variability-will be a critical determinant of the infringement analysis.